Canada-based Edesa Biotech, Inc. (Nasdaq: EDSA) announced the pricing of a USD 25 million underwritten public offering on August 19, 2026, with proceeds directed toward advancing its dermatology and respiratory pipeline at a moment when both programs are entering active clinical execution. The raise arrives one week after the company reported cash and cash equivalents of USD 10.3 million as of June 30, 2026, alongside a quarterly net loss of USD 5.4 million — underscoring the need for additional runway as the Phase II vitiligo study moves into enrollment.
The offering comprises 3,870,500 common shares and up to 675,000 pre-funded warrants, each sold with an accompanying common share warrant, at a combined price of USD 5.50 per unit. The accompanying warrants (exercise price USD 7.50 per share) are immediately exercisable, expiring on the earlier of 18 months from issuance or 30 days following Edesa's public announcement of Phase II topline vitiligo data for EB06 — a structure that directly ties warrant duration to the program's most anticipated near-term catalyst. Edesa also granted underwriters a 30-day option to purchase up to an additional 681,825 shares and accompanying warrants. Edesa previously raised USD 3.5 million via a CEO-led private placement completed in June 2026.
The primary asset supported by this financing is EB06, an anti-CXCL10 monoclonal antibody candidate in a Phase II study for moderate-to-severe non-segmental vitiligo. Edesa completed preparations for the trial during Q3 2026 and began activating its first investigational sites in Canada, with additional jurisdictions pending regulatory approval.